Fischer Medical Q1 FY27 Results (NSE: FISCHER)

· Analysis by Alpha Inflection

Signal: Growth reaccelerated

The read

The key inflection is a recovery from Q4FY26's 1.02% operating margin and ₹1,243.74 lakh consolidated loss to Q1FY27's 15.6% EBITDA margin and ₹379.13 lakh profit, but the trajectory is not yet re-established: margin remains below Q1-Q3FY26's 18.2%-21.3% range, gross margin compressed 1,663bps YoY as material costs reached 53.7% of revenue, finance cost rose 436.2%, and EPS fell 92.2% because of dilution and the weak comparison.

Fischer Medical Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹81.92 Cr249.5%-16.0%
EBIT₹11.38 Cr3.8%
Net profit₹3.79 Cr-24.4%
EPS₹0.06-92.2%
EBIT margin15.6%

P&L walk

Revenue rose to ₹8,192.00 lakh, +249.5% YoY but -16.0% QoQ; gross margin compressed 1,663bps YoY to 28.9% as cost of materials rose to 53.7% of revenue from 0.9%, while EBITDA margin fell to 15.6%, finance cost increased 436.2% YoY to ₹354.30 lakh and PAT declined 24.4% to ₹379.13 lakh.

Segments

No segment table is provided, but the standalone parent generated only ₹72.17 lakh of revenue and a ₹350.41 lakh loss versus consolidated revenue of ₹8,192.00 lakh and PAT of ₹379.13 lakh, confirming that earnings sit in subsidiaries.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.